Sonire Therapeutics Inc.
As of April 2024
City | Year of Establishment | Founder |
---|---|---|
Tokyo Chuo-ku | 2020 |
|
Partner VC | Latest round of Fundraising | Valuation |
---|---|---|
- | Series B | JPY 5,000 million |
- Contact Information : info@sonire-t.com
- Website : Sonire Therapeutics Inc.
Program name
Deep-Tech Startups Support Program
Research theme
Research and development for practical application of next-generation focused ultrasound therapy system for refractory cancer
Business Plan
The objective of our business is to develop a next-generation High-Intensity Focused Ultrasound (HIFU) treatment device and obtain its approval as a medical device through clinical trials, thereby providing a new treatment method for pancreatic cancer and other cancer patients. This project focuses on cavitation bubbles and aims to dramatically improve safety by developing a "next-generation type" that can visualize cavitation bubbles, and to obtain regulatory approval and insurance coverage in developed countries.
Research Outline
This grant project will accelerate the implementation of pancreatic cancer clinical trials in Japan and expansion to other oncologies, as well as pancreatic cancer clinical trials in the United States, which is the largest market.
In addition, by achieving the PoC listed below, we aim to achieve the following
- Conduct and accelerate domestic clinical trials (pancreatic cancer)
- Start domestic clinical trials (other than pancreatic cancer)
- Start of clinical trials (pancreatic cancer) in the U.S.
Phase | Business Area/Field | Research Period | Research Grant Amount |
---|---|---|---|
PCA | Healthcare | 22023 - 2025FY | JPY 971 million |
International collaborative technology demonstration
Countries/Regions | Collaborative activity outline |
---|---|
United States |
|
Last Updated : June 14, 2024